Public disclosures

Apuli Maricel

Company insiders · Chief Accounting Officer · BridgeBio Pharma, Inc.

Advertisement
FollowLatest SEC filingSEC filer historyProfile details as reported on 2026-11-18.Following & alerts
Reported transaction lines
2
Buy lines
0
Sell lines
1

Filing activity by month

Original filing lines in up to 12 months with activity.

  • 2026-112

Frequently disclosed stocks

Disclosure history

More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSource
Apuli Maricel

Chief Accounting Officer · BridgeBio Pharma, Inc.

BBIO

BridgeBio Pharma, Inc.

Other transaction
Filing details

SEC transaction code F

Common Stock · Direct ownership · Reported balance after transaction: 115973 · Securities delivered or withheld for tax or exercise payment · Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 9,261 shares of Common Stock underlying the Reporting Person's RSUs.

2026-11-162026-11-18

4,714 shares/units

SEC 4
Apuli Maricel

Chief Accounting Officer · BridgeBio Pharma, Inc.

BBIO

BridgeBio Pharma, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 120687 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 8, 2025.

2026-10-302026-11-03

≈ $145,700.00

2,000 shares/units

SEC 4

Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.

Advertisement